We are studying the effects of PLX038 in patients with locally advanced or metastatic triple-negative breast cancer. The goal is to see how well it works and to understand its safety and tolerability.
Health conditions and diseases that the clinical trial is designed to study and treat.
Advanced triple-negative breast cancer is a type of breast cancer that lacks three common receptors known to fuel most breast cancer growth. It is often more aggressive and can spread to other parts of the body.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.